An ongoing dialogue on HIV/AIDS, infectious diseases,
May 25th, 2012
Generic Nevirapine Now Available — But the Big One is Next Year
As I’m sure you’ve heard from your patients — as I did — lamivudine (3TC) is now available generically. Now comes news of the release of several generic formulations of nevirapine (NVP), an effective but always somewhat overshadowed medication. Since its approval way back when in 1996, there has always been a solid reason to pick […]
July 25th, 2009
IAS Cape Town 2009: Some Greatest Hits
Below is a highly-subjective list of some of the highlights from the Cape Town IAS meeting. I’m sure I missed something — it’s impossible to see everything at these large conferences. Corrections/additions welcome! My miss-rate might be particularly high since the international AIDS meetings are appropriately focused on HIV treatment in resource-limited settings (especially Africa) whereas […]
July 10th, 2009
Time for a Switch? What Actually Happened
A couple of months ago, I presented these three clinically stable, virologically suppressed patients — and asked if they should switch treatment: 50 year old man on ABC/3TC, EFV since 2000. No renal disease. Hyperlipidemia, on atorvastatin 80 mg a day. Father died of an MI age 48. 63 year old man, on EFV + LPV/r […]
Paul E. Sax, MD
Contributing Editor
NEJM Journal Watch
Infectious Diseases
Biography | Disclosures | Summaries
Learn more about HIV and ID Observations.
NEJM Journal Watch — Recent Infectious Disease Articles- Rising Rates of Perinatal HIV: Maryland, 2022
- Do Children Need a Booster of Typhoid Conjugate Vaccine?
- Infection with Tecovirimat-Resistant Mpox Virus Is on the Rise in the U.S.
- Kidney Transplantation: Offering HOPE for Those with HIV
- Observations from ID and Beyond: Brave New Name — How PCP Became PJP and Why It Matters